Scholarlink

Purpose <p>Astrocytes colocalize with fibrillar amyloid-β (Aβ) plaques in postmortem Alzheimer’s disease (AD) brain tissue; however, their spatiotemporal dynamics in vivo remain poorly understood. This multicenter study aimed to investigate the progression of astrocyte reactivity across the AD continuum, including healthy controls (HC), mild cognitive impairment (MCI), and AD, using the novel monoamine oxidase B (MAO-B)-specific PET tracer [<sup>18</sup>F]SMBT-1, while exploring its association with cognitive performance and amyloid burden.</p> Methods <p>A total of 91 participants (35 HC, 44 MCI, 12 AD) underwent [<sup>18</sup>F]SMBT-1 PET, amyloid PET, T1-weighted MRI, and standardized neuropsychological assessments. Standardized uptake value ratios (SUVRs) were calculated based on [<sup>18</sup>F]SMBT-1 PET data using four reference regions for subgroup comparisons stratified by Aβ status.</p> Results <p>[<sup>18</sup>F]SMBT-1 uptake was significantly elevated in amyloid-positive MCI (MCI+) and AD groups compared with amyloid-negative HC (HC−) in the frontal, temporal, and posterior cingulate regions. Notably, astrogliosis patterns distinguished MCI subtypes: MCI+ individuals exhibited a widespread AD-like pattern, whereas the MCI− group showed a distinct profile. Furthermore, the uptake in symptomatic MCI+ individuals was significantly higher than that in asymptomatic HC+ individuals. Regional SMBT-1 uptake also strongly correlated with greater Aβ burden and worse cognitive scores.</p> Conclusion <p>This study demonstrates that [<sup>18</sup>F]SMBT-1 is a promising tool for characterizing the spatial pattern and magnitude of reactive astrogliosis across the Aβ-defined AD continuum. Our findings further suggest that astrogliosis may represent an important mechanistic link between amyloid pathology and cognitive impairment, supporting its potential relevance in therapeutic development.</p> Clinical trial registration <p>Japan Registry of Clinical Trials (jRCT) jRCTs031210602, registered Feb. 07, 2022.</p> URL for the trial registry <p><a href="https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031210602">https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031210602</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Astrocyte reactivity across the AD continuum measured by [18F]SMBT-1 and its relationship with the Aβ burden

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月6日

查看全文
  • Yingying Wu,
  • Kotaro Hiraoka,
  • Berihu Mesfin,
  • Asuka Kikuchi,
  • Shoichi Watanuki,
  • Shunji Mugikura,
  • Naoki Tomita,
  • Aiko Ishiki,
  • Katsutoshi Furukawa,
  • Yoshihito Funaki,
  • Jun Toyohara,
  • Yasuyuki Kimura,
  • Ryuichi Harada,
  • Shozo Furumoto,
  • Akio Kikuchi,
  • Hiroshi Watabe,
  • Ryota Kobayashi,
  • Takashi Nihashi,
  • Takashi Kato,
  • Kenji Ishii,
  • Shinobu Kawakatsu,
  • Nobuyuki Okamura,
  • Manabu Tashiro,
  • Yoichi Ishikawa,
  • Kazuko Takeda,
  • Kazuhiko Yanai,
  • Miho Shidahara,
  • Masayasu Miyake,
  • Mizue Kusaba,
  • Kei Takase,
  • Taizen Nakase,
  • Tatsushi Mutoh,
  • Yasuyuki Taki,
  • Mari Otshuki,
  • Tadaho Nakamura,
  • Fumito Naganuma,
  • Tomonori Matsuura,
  • Kenji Ishibashi,
  • Tetsuro Tago,
  • Muneyuki Sakata,
  • Yuto Kamitaka,
  • Etsuko Imabayashi,
  • Masashi Kameyama,
  • Mika Tanaka,
  • Keita Sakurai,
  • Kengo Ito,
  • Akinori Nakamura,
  • Keisuke Suzuki,
  • Masashi Tsujimoto,
  • Hiroshi Ikenuma,
  • Junichiro Abe,
  • Kaori Iwata,
  • Daichi Morioka,
  • Masafumi Kanoto,
  • Kazukuni Kirii,
  • Kenichi Utano

摘要

Purpose

Astrocytes colocalize with fibrillar amyloid-β (Aβ) plaques in postmortem Alzheimer’s disease (AD) brain tissue; however, their spatiotemporal dynamics in vivo remain poorly understood. This multicenter study aimed to investigate the progression of astrocyte reactivity across the AD continuum, including healthy controls (HC), mild cognitive impairment (MCI), and AD, using the novel monoamine oxidase B (MAO-B)-specific PET tracer [18F]SMBT-1, while exploring its association with cognitive performance and amyloid burden.

Methods

A total of 91 participants (35 HC, 44 MCI, 12 AD) underwent [18F]SMBT-1 PET, amyloid PET, T1-weighted MRI, and standardized neuropsychological assessments. Standardized uptake value ratios (SUVRs) were calculated based on [18F]SMBT-1 PET data using four reference regions for subgroup comparisons stratified by Aβ status.

Results

[18F]SMBT-1 uptake was significantly elevated in amyloid-positive MCI (MCI+) and AD groups compared with amyloid-negative HC (HC−) in the frontal, temporal, and posterior cingulate regions. Notably, astrogliosis patterns distinguished MCI subtypes: MCI+ individuals exhibited a widespread AD-like pattern, whereas the MCI− group showed a distinct profile. Furthermore, the uptake in symptomatic MCI+ individuals was significantly higher than that in asymptomatic HC+ individuals. Regional SMBT-1 uptake also strongly correlated with greater Aβ burden and worse cognitive scores.

Conclusion

This study demonstrates that [18F]SMBT-1 is a promising tool for characterizing the spatial pattern and magnitude of reactive astrogliosis across the Aβ-defined AD continuum. Our findings further suggest that astrogliosis may represent an important mechanistic link between amyloid pathology and cognitive impairment, supporting its potential relevance in therapeutic development.

Clinical trial registration

Japan Registry of Clinical Trials (jRCT) jRCTs031210602, registered Feb. 07, 2022.

URL for the trial registry

https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031210602.